The clinical use of Alzheimer’s disease biomarkers in patients with mild cognitive impairment: a European Alzheimer’s Disease Consortium survey

Manuscript Number: 

22-0333R2

Author(s): 
Gilles Allali, Daniele Altomare, Frédéric Assal, Camilla Caprioglio, Giovanni B. Frisoni, Lutz Frölich, Valentina Garibotto, Frank Jessen

Disclosures

Gilles Allali

  • Nothing to Disclose

Daniele Altomare

  • Nothing to Disclose

Frédéric Assal

  • Nothing to Disclose

Camilla Caprioglio

  • Nothing to Disclose

Giovanni B. Frisoni

  • Consulting Fees:
    Personal fees from AstraZeneca, Avid Radiopharmaceuticals, Biogen, Roche, Diadem, Neurodiem, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics
    Grants
    • Agency: 
      Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, IXICO, Merz Pharma, Nestlé, Novartis, Eisai, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, and Vifor Pharma
      Dates: 
      2022

Lutz Frölich

  • Consulting Fees:
    Consultant for Abbott, Allergan, Axon Neuroscience, Biogen, Eisai, Hummingbird, InfectoPharm, MerckSharpe & Dohme, Neurimmune, Neuromodulation, Noselab, NovoNordisk, Roche, Schwabe
    Lecture Fees:
    Speaker for Roche, Schwabe
    Grants
    • Agency: 
      Axon Neuroscience, Eisai, Anavex, Alector, Boehringer Ingelheim
      Dates: 
      2019-2021

Valentina Garibotto

  • Consulting Fees:
    Received through my institution from Avid Radiopharmaceuticals.
    Lecture Fees:
    Support through my institution from Siemens Healthineers, GE Healthcare, Novo Nordisk

Frank Jessen

  • Nothing to Disclose